Skip to main content
Signal8

Kymera Therapeutics, Inc. (KYMR)

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc.

NASDAQ:KYMRHealthcare
+2.82%$131.73
CLOSED
AH$131.07-0.50%vs close
Mkt Cap$11.25B
Float67.09M
O/S85.37M
VOL787K sh
$ Vol$102.79M
RVOL0.82×
Inst Own-
SI13.7%
Dilution
Kymera Therapeutics, Inc. logoNASDAQ:KYMRClosed$131.73+2.82%
Historical Data
DateOpenHighLowCloseVolume
Nov 6, 2026129.41132.68126.65131.73786,960
Nov 5, 2026137.54138.00124.22128.121,728,951
Nov 4, 2026128.67136.57126.12136.251,824,460
Nov 3, 2026128.79133.88126.48127.091,401,505
Nov 2, 2026127.00129.34124.30127.511,294,514
Oct 30, 2026122.58127.26117.31126.631,591,508
Oct 29, 2026127.00127.74117.74122.601,045,368
Oct 28, 2026116.17122.91115.46122.51768,151
Oct 27, 2026114.52119.68111.14117.57828,870
Oct 26, 2026111.96115.22110.31114.84438,576
Oct 23, 2026110.85111.83109.05110.76517,065
Oct 22, 2026111.43113.74110.13110.85850,270
Oct 21, 2026113.38115.75112.52112.631,056,300
Oct 20, 2026108.75115.28108.49113.46705,158
Oct 19, 2026106.56109.16105.10108.07683,373
Oct 16, 2026108.19108.59104.39104.78489,328
Oct 15, 2026106.75110.68104.63108.14820,992
Oct 14, 2026106.39108.08105.58106.831,029,093
Oct 13, 2026110.83112.06106.52106.68779,110
Oct 12, 2026111.61113.13110.52112.08537,523
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target (median, last 90d)
$175.00+32.8%
Low $170High $180
Ratings Distribution
BUY
24
HOLD
3
SELL
0
TOTAL27
Insider Trades
InsiderTypeShares
Mainolfi Nello profile photoMainolfi NelloSale4.9K
Mainolfi Nello profile photoMainolfi NelloOption Exercise30.0K
Mainolfi Nello profile photoMainolfi NelloSale8.2K
Mainolfi Nello profile photoMainolfi NelloSale5.5K
Mainolfi Nello profile photoMainolfi NelloSale262
Mainolfi Nello profile photoMainolfi NelloOption Exercise30.0K
Shareholders
-
Institutionalⓘ
(294)
1.5%
Insiderⓘ
(10)
7.0%
5%+ Owners
(2)
-
Unattributed (incl. retail)ⓘ
Insider1.5%
5%+ Beneficial7.0%
Sources: 13F, Form 4, 13D/13GO/S: 85.4M · as of 23 Oct 2026 · SEC cover page
Insiders & Institutional Holders

Insiders

Top institutional holders

About

Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins.

The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis.

Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors.

The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.

Key Metrics
Market Cap$11.25B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership-

13F filers report 97.56M shares, more than the 85.37M outstanding, so no percentage is shown. 13F reports lag by a quarter and shares lent to short sellers can be counted twice.

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateAug 21, 2020
Shares Outstanding85.37M
Authorized Shares
Float67.09M
52-Week Range
$56.75$138.00
$131.73(92nd percentile)
Volume
Average Daily Volume958.85K
786.96K today vs 958.85K avg(-18%)

30d Avg

958.85K

60d Avg

915.30K

90d Avg

822.49K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...